Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, such as a flu vaccine patch, announced Monday that it will offer 6.3 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market capitalization $218 million. UBS Investment Bank and SG Cowen will lead manage the deal. Timing has yet to be disclosed.
